Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of the biosimilar candidate of adalimumab (HS016) compared with adalimumab (Humira) for the treatment of active ankylosing spondylitis. METHODS: A multicenter, randomized, double-blind, parallel, positive control, phase III cli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BioDrugs
Hauptverfasser: Su, Jinmei, Li, Mengtao, He, Lan, Zhao, Dongbao, Wan, Weiguo, Liu, Yi, Xu, Jianhua, Xu, Jian, Liu, Huaxiang, Jiang, Lindi, Wu, Huaxiang, Zuo, Xiaoxia, Huang, Cibo, Liu, Xiumei, Li, Fen, Zhang, Zhiyi, Liu, Xiangyuan, Dong, Lingli, Li, Tianwang, Chen, Haiying, Li, Jingyang, He, Dongyi, Lu, Xin, Huang, Anbin, Tao, Yi, Wang, Yanyan, Zhang, Zhuoli, Wei, Wei, Li, Xiaofeng, Zeng, Xiaofeng
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer International Publishing 2020
Schlagworte:
Original Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7211209/
https://ncbi.nlm.nih.gov/pubmed/32078145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-020-00408-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge